- Home
- MYO vs ITRM Comparison
MYO vs ITRM Comparison
Compare MYO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- ITRM
- Stock Information
- Founded
- MYO 2004
- ITRM 2015
- Country
- MYO United States
- ITRM Ireland
- Employees
- MYO N/A
- ITRM N/A
- Industry
- MYO Industrial Specialties
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- ITRM Health Care
- Exchange
- MYO Nasdaq
- ITRM Nasdaq
- Market Cap
- MYO 44.6M
- ITRM 40.0M
- IPO Year
- MYO 2017
- ITRM 2018
- Fundamental
- Price
- MYO $0.87
- ITRM $0.68
- Analyst Decision
- MYO Strong Buy
- ITRM Strong Buy
- Analyst Count
- MYO 3
- ITRM 2
- Target Price
- MYO $8.17
- ITRM $7.00
- AVG Volume (30 Days)
- MYO 1.5M
- ITRM 723.5K
- Earning Date
- MYO 11-05-2025
- ITRM 11-13-2025
- Dividend Yield
- MYO N/A
- ITRM N/A
- EPS Growth
- MYO N/A
- ITRM N/A
- EPS
- MYO N/A
- ITRM N/A
- Revenue
- MYO $40,760,091.00
- ITRM N/A
- Revenue This Year
- MYO $25.69
- ITRM N/A
- Revenue Next Year
- MYO $23.52
- ITRM $249.35
- P/E Ratio
- MYO N/A
- ITRM N/A
- Revenue Growth
- MYO 93.08
- ITRM N/A
- 52 Week Low
- MYO $0.81
- ITRM $0.61
- 52 Week High
- MYO $7.17
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- MYO 25.21
- ITRM 43.41
- Support Level
- MYO $0.81
- ITRM $0.64
- Resistance Level
- MYO $1.01
- ITRM $0.76
- Average True Range (ATR)
- MYO 0.07
- ITRM 0.05
- MACD
- MYO 0.02
- ITRM 0.01
- Stochastic Oscillator
- MYO 17.29
- ITRM 50.69
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.